Buscar
28/03/2024
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study
Kassubek, J, Factor, SA, Balaguer, E, Schwarz, J, Chaudhuri, KR, Isaacson, SH, Wu, S, Muhr, CD, Kulisevsky, J. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study. JOURNAL OF NEUROLOGY. 2024; 271(6)DOI:10.1007/s00415-024-12323-2. PMID:38546829. IF:4.600(Q1/2D).
28/03/2024
A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors
Swift, IJ, Rademakers, R, Finch, N, Baker, M, Ghidoni, R, Benussi, L, Binetti, G, Rossi, G, Synofzik, M, Wilke, C, Mengel, D, Graff, C, Takada, LT, Sanchez-Valle, R, Antonell, A, Galimberti, D, Fenoglio, C, Serpente, M, Arcaro, M, Schreiber, S, Vielhaber, S, Arndt, P, Santana, I, Almeida, MR, Moreno, F, Barandiaran, M, Gabilondo, A, Stubert, J, Gomez-Tortosa, E, Agueero, P, Sainz, MJ, Gohda, T, Murakoshi, M, Kamei, N, Kittel-Schneider, S, Reif, A, Weigl, J, Jian, JL, Liu, CJ, Serrero, G, Greither, T, Theil, G, Lohmann, E, Gazzina, S, Bagnoli, S, Coppola, G, Bruni, A, Quante, M, Kiess, W, Hiemisch, A, Jurkutat, A, Block, MS, Carlson, AM, Bråthen, G, Sando, SB, Grontvedt, GR, Lauridsen, C, Heslegrave, A, Heller, C, Abel, E, Gómez-Núñez, A, Puey, R, Arighi, A, Rotondo, E, Jiskoot, LC, Meeter, LHH, Duraes, J, Lima, M, Tábuas-Pereira, M, Lemos, J, Boeve, B, Petersen, RC, Dickson, DW, Graff-Radford, NR, Leber, I, Sellami, L, Lamari, F, Clot, F, Borroni, B, Cantoni, V, Rivolta, J, Lleó, A, Fortea, J, Alcolea, D, Illán-Gala, I, Andres-Cerezo, L, Van Damme, P, Clarimon, J, Steinacker, P, Feneberg, E, Otto, M, van der Ende, EL, van Swieten, JC, Seelaar, H, Zetterberg, H, Sogorb-Esteve, A, Rohrer, JD. A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors. Alzheimers Research & Therapy. 2024; 16(1)DOI:10.1186/s13195-024-01420-z. PMID:38539243. IF:7.600(Q1/1D).
28/03/2024
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine
de Lazzari, E, Negredo, EB, Domingo, P, Tiraboschi, JM, Ribera, E, Abdulghani, N, Alba, V, Fernández-Arroyo, S, Viladés, C, Peraire, J, Gatell, JM, Blanco, JL, Vidal, F, Rull, A, Martinez, E. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(5)DOI:10.1093/jac/dkae083. PMID:38546974. IF:3.600(Q2/3D).
28/03/2024
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020
Nomah, DK, Jamarkattel, S, Bruguera, A, Moreno-Fornés, S, Díaz, Y, Alonso, L, Aceitón, J, Llibre, JM, Domingo, P, Saumoy, M, Homar, F, Fanjul, F, Navarro, J, de la Mora, L, Knobel, H, Orti, A, Martin-Iguacel, R, Miró, JM, Casabona, J, Reyes-Urueña, J. Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020. Open Forum Infectious Diseases. 2024; 11(4)DOI:10.1093/ofid/ofae132. PMID:38560603. IF:3.800(Q1/3D).
27/03/2024
Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease
Martinez-Horta, S, Perez-Perez, J, Perez-Gonzalez, R, Sampedro, F, Horta-Barba, A, Campolongo, A, Rivas-Asensio, E, Puig-Davi, A, Pagonabarraga, J, Kulisevsky, J. Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease. Annals of Clinical and Translational Neurology. 2024; 11(5)DOI:10.1002/acn3.52031. PMID:38544341. IF:3.900(Q1/3D).
27/03/2024
C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project
Arnold, N, Blaum, C, Gossling, A, Brunner, FJ, Bay, B, Ferrario, MM, Brambilla, P, Cesana, G, Leoni, V, Palmieri, L, Donfrancesco, C, Padró, T, Andersson, J, Jousilahti, P, Ojeda, F, Zeller, T, Linneberg, A, Söderberg, S, Iacoviello, L, Gianfagna, F, Sans, S, Veronesi, G, Thorand, B, Peters, A, Tunstall-Pedoe, H, Kee, F, Salomaa, V, Schnabel, RB, Kuulasmaa, K, Blankenberg, S, Koenig, W, Waldeyer, C. C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project. EUROPEAN HEART JOURNAL. 2024; 45(12)DOI:10.1093/eurheartj/ehad867. PMID:38240386. IF:35.600(Q1/1D).